Tvardi Therapeutics, Inc. TVRD
1.27
0.21
19.81%
as of 25 Sep
- Market cap
- $14.7M
- P/E
- 0.0×
Follow TVRD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (126.19%) | (480.07%) | 51.90% | 19.93% |
+8 more TTM periods Free account |
|
| (85.08%) | (47.68%) | (54.15%) | 6.30% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(326.11%) | (109.40%) | (88.64%) | 10.37% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(2.67) | (2.31) | (3.17) | (2.42) | |
Free Cash Flow |
(25.03) | (21.67) | (23.50) | (22.65) | |
| Other line items | |||||
Cash ROIC |
(103.65%) | (54.88%) | (45.40%) | (35.21%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | (2.20) | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 1.40 | 1.29 | (7.95) | |
Depreciation/Fixed assets |
(2.92) | (2.39) | (2.02) | 1.58 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.67) | (2.31) | (3.17) | (2.42) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates